All In Biotech

Free tool

FAERS Monitor: Starjemza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761419 or its brand name (Starjemza, Ustekinumab-Hmny). Reports on generic versions are filed under their own applications.

Reports

1

Serious

1

100% of reports

Hospitalization

1

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • blood glucose increased1
  • drug ineffective1
  • dyspnoea1
  • hepatic cirrhosis1
  • nasopharyngitis1
  • pain1
  • pain in extremity1
  • peripheral swelling1
  • polyp1
  • psoriatic arthropathy1
  • skin reaction1
  • therapy interrupted1
  • tremor1

Reports by year received

View as table
YearReports
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,158 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
polyp13212.93136.1802
skin reaction11493.01468.6372
hepatic cirrhosis11119.91104.0279
psoriatic arthropathy1518.2513.2129
therapy interrupted1294.3292.273
peripheral swelling1136.5135.933
tremor1126.7126.131
nasopharyngitis1114.1113.628
blood glucose increased1111.6111.127
pain in extremity171.471.117
dyspnoea137.237.19
pain134.234.28
drug ineffective116.015.93

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.